RxDoctor Payments Data

Pedro Falla, MD

Internal Medicine · New Bedford, MANPI 1811096977

Payments from drug & device makers

$878in general payments, 2019–2025

Across 55 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$242
  • AbbVie$228
  • E.r. Squibb & Sons, L.L.C.$105
  • GSK$81
  • Johnson & Johnson$75
  • Novo Nordisk$31
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$86799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$77,913
Medicare patients
266
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide177$181,348
EliquisApixaban131$122,968
JardianceEmpagliflozin88$94,036
OzempicSemaglutide80$88,501
JanuviaSitagliptin Phosphate71$77,365
FarxigaDapagliflozin Propanediol34$46,966
LinzessLinaclotide26$33,103
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$33,100
XareltoRivaroxaban27$28,742
Breo ElliptaFluticasone/Vilanterol46$20,766
VascepaIcosapent Ethyl29$18,072
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$16,836
Rosuvastatin Calcium598$16,068
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate56$13,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog129$13,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$242$122,968131 claims
Boehringer IngelheimJardiance$14$94,03688 claims
Novo NordiskOzempic$31$88,50180 claims
MerckJanuvia$25$77,36571 claims
AstraZenecaFarxiga, Symbicort, Pulmicort Flexhaler$27$66,54496 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$81$63,718120 claims
AbbVieLinzess$228$33,10326 claims
Johnson & JohnsonXarelto$75$28,74227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in New Bedford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →